gp100 antigen

also known as gp100:209-217(210M) · gp100 · Gp100 glycoprotein · gp100:17-25 · Melanocyte protein pmel · Melanocyte protein pmel 17 · Melanoma-associated me20 antigen · modified gp100 peptide · +1 more

Peptide

Trials 25

today NCT00470015 · Ph 1 NCT00303836 · Ph 2 NCT00091143 · Ph 1 NCT00089063 · Ph 2 NCT00085189 · Ph 2 NCT00085397 · Ph 2 NCT00077532 · Ph 2 NCT00031733 · Ph 2 NCT00032045 · Ph 2 NCT00020475 · Ph 2 NCT00010309 · Ph 1/2 NCT00006243 · not/applicable NCT00020358 · Ph 2 NCT00005841 · Ph 1 NCT00019669 · Ph 2 NCT00019994 · Ph 2 NCT00019721 · Ph 2 NCT00003568 · Ph 2 NCT00003339 · Ph 2 NCT00019448 · Ph 2 NCT00003362 · Ph 2 NCT00003222 · Ph 2 NCT00003274 · Ph 2 NCT00003229 · Ph 1/2 NCT00019175 · Ph 1

19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 14 trials
Phase 1	NCT00470015	Mar 2007 → Apr 2009	cutaneous melanoma	Mayo Clinic	Completed	No outcome recorded
Phase 1	NCT00091143	Jul 2004 → Mar 2010	cutaneous melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00005841	Jun → Dec 2000	cutaneous melanoma, ocular melanoma	University of Southern California	Terminated	No outcome recorded
Phase 1	NCT00019175	Aug 1996 → ?	cutaneous melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT00010309	Nov 2000 → ?	cutaneous melanoma	Genzyme, a Sanofi Company	Unknown	No outcome recorded
Phase 1/2	NCT00003229	Jul 1997 → Apr 2000	cutaneous melanoma	Duke University	Completed	No outcome recorded
Phase 218 trials
Phase 2	NCT00303836	Nov 2005 → Jan 2007	metastatic melanoma	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 2	NCT00089063	Jun 2004 → Jun 2007	iris melanoma, medium/large size posterior uveal melanoma, ocular melanoma with extraocular extension	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00085189	May 2004 → Sep 2007	iris melanoma, medium/large size posterior uveal melanoma, mucosal melanoma, ocular melanoma with extraocular extension +1	University of Southern California	Completed	No outcome recorded
Phase 2	NCT00085397	Mar 2004 → ?	cutaneous melanoma	Dana-Farber Cancer Institute	Unknown	No outcome recorded
Phase 2	NCT00077532	Mar 2004 → Jan 2007	cutaneous melanoma	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 2	NCT00031733	Feb 2002 → Dec 2004	cutaneous melanoma, ocular melanoma	University of Southern California	Completed	No outcome recorded
Phase 2	NCT00032045	Jan 2002 → Aug 2006	cutaneous melanoma, ocular melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00020475	Feb 2001 → Mar 2007	ocular melanoma with extraocular extension	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00020358	Sep 2000 → Oct 2007	cutaneous melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00019669	Oct 1999 → Oct 2007	cutaneous melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00019994	Oct 1999 → Oct 2007	cutaneous melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00019721	Apr 1999 → Jun 2003	cutaneous melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00003568	Nov 1998 → Dec 2005	cutaneous melanoma	University of Illinois at Chicago	Completed	No outcome recorded
Phase 2	NCT00003339	Nov 1998 → Nov 1999	cutaneous melanoma, ocular melanoma	University of Southern California	Completed	No outcome recorded
Phase 2	NCT00019448	Sep 1998 → Mar 2007	melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00003362	May 1998 → Feb 2001	cutaneous melanoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00003222	Apr 1998 → Sep 2003	cutaneous melanoma	University of Virginia	Completed	No outcome recorded
Phase 2	NCT00003274	Mar 1998 → Sep 2001	cutaneous melanoma	University of Southern California	Completed	No outcome recorded

Phase not applicable1 trial
—	NCT00006243	Oct 2000 → May 2006	melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Comparator or background therapy3 trials
Phase 1	NCT00091338 Background	Aug 2004 → ?	cutaneous melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00025181 Background	Oct 2001 → Jan 2003	cutaneous melanoma, ocular melanoma	University of Southern California	Completed	No outcome recorded
Phase 1	NCT00003665 Background	Apr 1999 → Oct 2002	cutaneous melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 30 sources stand behind the page.

Field	Value	Cited text
Known as	gp100 antigen	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00019721 ↗ 27 NCT00003222 ↗ NCT00031733 ↗ NCT00077532 ↗ NCT00019994 ↗ NCT00025181 ↗ NCT00085189 ↗ NCT00010309 ↗ NCT00470015 ↗ NCT00089063 ↗ NCT00003229 ↗ Show 17 more sources
Known as	gp100	“The melanoma tumor antigen epitope peptides MART-1(26-35 (27L)), gp100(209-217 (210M)),and tyrosinase(368-376 (370D)) were emulsified with incomplete Freund's adjuvant and...” PMID 12684398 ↗ Apr 2003
Known as	Gp100 glycoprotein	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297963 ↗
Known as	gp100:17-25	“peptide immunization with gp100:209-217 (210M) or gp100:17-25 antigen” NCT00020358 ↗
Known as	gp100:209-217(210M)	“Define the antitumor activity of gp100:209-217 (210M), a melanoma peptide derived from gp100 mixed with Montanide ISA-51, in combination with high-dose interleukin-2 (IL-2)...” NCT00003568 ↗ 2 “vaccination comprising modified gp100 peptide (gp100:209-217\[210M\]), Montanide ISA-51, and keyhole limpet hemocyanin” NCT00091143 ↗ “peptide immunization with gp100:209-217 (210M) or gp100:17-25 antigen” NCT00020358 ↗
Known as	Melanocyte protein pmel	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297963 ↗
Known as	Melanocyte protein pmel 17	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297963 ↗
Known as	Melanoma-associated me20 antigen	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297963 ↗
Known as	modified gp100 peptide	“vaccination comprising modified gp100 peptide (gp100:209-217\[210M\]), Montanide ISA-51, and keyhole limpet hemocyanin” NCT00091143 ↗
Known as	Premelanosome protein	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297963 ↗
Action	Deplete	“Vaccines made from peptides may make the body build an immune response to kill tumor cells.” NCT00089063 ↗
Modality	Peptide	“mixture of synthetic melanoma peptides” NCT00003222 ↗
Route	Subcutaneous	“vaccine comprising tyrosinase peptide and gp100 antigen emulsified in Montanide ISA-51 (ISA-51) alone subcutaneously (SQ) once a week” NCT00003274 ↗